325 related articles for article (PubMed ID: 24510638)
1. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Silber S; Kirtane AJ; Belardi JA; Liu M; Brar S; Rothman M; Windecker S
Eur Heart J; 2014 Aug; 35(29):1949-56. PubMed ID: 24510638
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.
Zhang YJ; Zhao YL; Xu B; Han YL; Li B; Liu Q; Su X; Pang S; Lu SZ; Guo XF; Yang YJ
Chin Med J (Engl); 2015 Mar; 128(6):714-20. PubMed ID: 25758261
[TBL] [Abstract][Full Text] [Related]
3. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
Kim BK; Hong MK; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Kang TS; Park BE; Kang WC; Lee SH; Yoon JH; Hong BK; Kwon HM; Jang Y;
J Am Coll Cardiol; 2012 Oct; 60(15):1340-8. PubMed ID: 22999717
[TBL] [Abstract][Full Text] [Related]
4. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.
Tandjung K; Sen H; Lam MK; Basalus MWZ; Louwerenburg JHW; Stoel MG; van Houwelingen KG; de Man FHAF; Linssen GCM; Saïd SAM; Nienhuis MB; Löwik MM; Verhorst PMJ; van der Palen J; von Birgelen C
J Am Coll Cardiol; 2013 Jun; 61(24):2406-2416. PubMed ID: 23602769
[TBL] [Abstract][Full Text] [Related]
6. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program.
Yeh RW; Silber S; Chen L; Chen S; Hiremath S; Neumann FJ; Qiao S; Saito S; Xu B; Yang Y; Mauri L
JACC Cardiovasc Interv; 2017 Feb; 10(3):247-254. PubMed ID: 28109872
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
[TBL] [Abstract][Full Text] [Related]
8. Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
Hahn JY; Song YB; Choi JH; Choi SH; Lee SY; Park HS; Hur SH; Lee S; Han KR; Rha SW; Cho BR; Park JS; Yoon J; Lim DS; Lee SH; Gwon HC;
Circ J; 2010 Nov; 74(11):2314-21. PubMed ID: 20938098
[TBL] [Abstract][Full Text] [Related]
9. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
[TBL] [Abstract][Full Text] [Related]
10. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
Cutlip DE; Kereiakes DJ; Mauri L; Stoler R; Dauerman HL;
JACC Cardiovasc Interv; 2015 Mar; 8(3):404-410. PubMed ID: 25703885
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
Kedhi E; Fabris E; van der Ent M; Kennedy MW; Buszman P; von Birgelen C; Cook S; Wedel H; Zijlstra F
Am Heart J; 2017 Jun; 188():11-17. PubMed ID: 28577666
[TBL] [Abstract][Full Text] [Related]
12. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
[TBL] [Abstract][Full Text] [Related]
13. Duration of dual antiplatelet therapy after various drug-eluting stent implantation.
Sharma A; Sharma SK; Vallakati A; Garg A; Lavie CJ; Mukherjee D; Marmur JD
Int J Cardiol; 2016 Jul; 215():157-66. PubMed ID: 27116326
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the 9-month intra-stent conditions and 2-year clinical outcomes after Resolute zotarolimus-eluting stent implantation between 3-month and standard dual antiplatelet therapy.
Fujimoto W; Sawada T; Toba T; Takahashi Y; Miyata T; Oishi S; Osue T; Onishi T; Takaya T; Shimane A; Taniguchi Y; Kawai H; Yasaka Y
J Cardiol; 2018 Jul; 72(1):66-73. PubMed ID: 29456058
[TBL] [Abstract][Full Text] [Related]
15. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes with 6 months dual antiplatelet therapy after implantation of biolimus-A9 drug eluting coronary stents.
Cockburn J; Pareek N; Poliacikova P; Saraf S; Williams R; Dhillon G; Robinson D; Gerber R; Hatrick R; Blows L; de Belder A; Hildick-Smith D
Int J Cardiol; 2014 Mar; 172(1):185-9. PubMed ID: 24462139
[TBL] [Abstract][Full Text] [Related]
17. Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy.
Tarantini G; Nai Fovino L; Tellaroli P; Chieffo A; Barioli A; Menozzi A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Dominguez JF; Steffanon L; Presbitero P; Pucci E; Fraccaro C; Mauri J; Giustino G; Sardella G; Colombo A
Int J Cardiol; 2016 Mar; 207():168-76. PubMed ID: 26803236
[TBL] [Abstract][Full Text] [Related]
18. Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial.
Han Y; Xu B; Xu K; Guan C; Jing Q; Zheng Q; Li X; Zhao X; Wang H; Zhao X; Li X; Yu P; Zang H; Wang Z; Cao X; Zhang J; Pang W; Li J; Yang Y; Dangas GD
Circ Cardiovasc Interv; 2016 Feb; 9(2):e003145. PubMed ID: 26858080
[TBL] [Abstract][Full Text] [Related]
19. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial.
Natsuaki M; Morimoto T; Yamamoto E; Shiomi H; Furukawa Y; Abe M; Nakao K; Ishikawa T; Kawai K; Yunoki K; Shimizu S; Akao M; Miki S; Yamamoto M; Okada H; Hoshino K; Kadota K; Morino Y; Igarashi K; Tanabe K; Kozuma K; Kimura T
Cardiovasc Interv Ther; 2016 Jul; 31(3):196-209. PubMed ID: 26518420
[TBL] [Abstract][Full Text] [Related]
20. Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
Youn YJ; Lee JW; Ahn SG; Lee SH; Choi H; Yu CW; Hong YJ; Kwon HM; Hong MK; Jang Y; Yoon J
Am Heart J; 2014 Feb; 167(2):241-248.e1. PubMed ID: 24439986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]